Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Oncogene
    August 2026
  1. GUILBARD M, Taouji S, Aubry M, Robert J, et al
    Complementary intra- and extracellular AGR2 activities support epithelial ovarian cancer cell aggressiveness.
    Oncogene. 2026 Aug 10. doi: 10.1038/s41388-026-03938.
    >> Share

    July 2026
  2. LI J, Zhou L, Yang S, Zhu Y, et al
    KLF12-mediated suppression of androgen receptor accelerates metastasis in endometrioid endometrial carcinoma by activating epithelial-mesenchymal transition.
    Oncogene. 2026 Jul 23. doi: 10.1038/s41388-026-03899.
    >> Share

    June 2026
  3. SUNDARARAJAN V, Ziyu F, Elfar GA, Tan TZ, et al
    Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.
    Oncogene. 2026 Jun 11. doi: 10.1038/s41388-026-03830.
    >> Share

  4. CHEN Y, Lu D, Xing Y, He J, et al
    The translation landscape of ovarian clear cell carcinoma indicates that RBM4 plays a pro-oncogenic role in tumor progression.
    Oncogene. 2026 Jun 5. doi: 10.1038/s41388-026-03840.
    >> Share

    May 2026
  5. LI Y, Chen Z, Diao Y, Gao Q, et al
    SNRPD2-CPSF7-UBE2K axis drives ovarian cancer progression via alternative splicing-polyadenylation crosstalk.
    Oncogene. 2026 May 7. doi: 10.1038/s41388-026-03812.
    >> Share

    April 2026
  6. WEI Y, Chen Z, Li Y, Song K, et al
    Correction: The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2026 Apr 23. doi: 10.1038/s41388-026-03810.
    >> Share

  7. LOBERMEYER A, Schollhorn JS, Rademacher PN, Wankner MC, et al
    Pre-operative circulating tumor cells predict worse treatment outcome in patients with high-grade serous ovarian cancer.
    Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03747.
    >> Share

  8. PU Y, Chen Z, Gao Q, Liu Y, et al
    Spliceosomal component SNRPE drives cell proliferation by regulating CTP synthase 1 mRNA splicing in ovarian cancer.
    Oncogene. 2026 Apr 4. doi: 10.1038/s41388-026-03764.
    >> Share

    March 2026
  9. PEI X, Wang F, Liu X, Lei Y, et al
    Core fucosylation of NCEH1 by FUT8 promotes progression of high-grade serous ovarian cancer by driving tumor-associated macrophage M2 polarization.
    Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03703.
    >> Share

  10. WEBB JD, Buensuceso A, Tomas EJ, Borrelli MJ, et al
    ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer.
    Oncogene. 2026 Mar 5. doi: 10.1038/s41388-026-03702.
    >> Share

    February 2026
  11. CHENG G, Jiang W, Li Z, Ma Y, et al
    TFAP2C protects against ferroptosis in ovarian cancer through the KEAP1-NRF2 axis by recruiting HDAC1/2.
    Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03692.
    >> Share

  12. XU J, Shi G, Qin Z, Yin B, et al
    Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK/ERK signaling.
    Oncogene. 2026 Feb 17. doi: 10.1038/s41388-026-03693.
    >> Share

  13. VISWANADHAPALLI S, Lee TK, Elmore S, Sharma G, et al
    Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer.
    Oncogene. 2026 Feb 6. doi: 10.1038/s41388-026-03689.
    >> Share

    January 2026
  14. SUN J, Cai X, Yung MMH, Zhou W, et al
    Retraction Note: miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2026 Jan 16. doi: 10.1038/s41388-026-03676.
    >> Share

    December 2025
  15. JI F, Yan K, Ding B, Zhu Y, et al
    Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity.
    Oncogene. 2025 Dec 17. doi: 10.1038/s41388-025-03663.
    >> Share

  16. LI Q, Zhang S, Wang M, Yi Q, et al
    Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Dec 5. doi: 10.1038/s41388-025-03656.
    >> Share

    November 2025
  17. LIU S, He Y, Ning X, Xu W, et al
    SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer.
    Oncogene. 2025 Nov 28. doi: 10.1038/s41388-025-03584.
    >> Share

    October 2025
  18. TANG S, Chen K, Zheng F, Fu Z, et al
    High serum LDL promotes EMT and stemness through LDLR/FOXQ1/NF-kappaB1 pathway in epithelial ovarian cancer.
    Oncogene. 2025 Oct 22. doi: 10.1038/s41388-025-03609.
    >> Share

  19. WU L, Wu C, He S, Chen Y, et al
    METAP2 inhibits K48-linked ubiquitination of YTHDF2 to promote ovarian cancer progression.
    Oncogene. 2025 Oct 16. doi: 10.1038/s41388-025-03594.
    >> Share

    September 2025
  20. HUANG L, Zhu M, Chen M, Ying F, et al
    LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer.
    Oncogene. 2025 Sep 10. doi: 10.1038/s41388-025-03561.
    >> Share

    August 2025
  21. LI Q, Zhang S, Wang M, Yi Q, et al
    Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition.
    Oncogene. 2025 Aug 12. doi: 10.1038/s41388-025-03522.
    >> Share

    July 2025
  22. SHEN C, Cao R, Zhou Q, Zhou T, et al
    LINC00654 promotes ovarian cancer progression by facilitating nuclear export of HuR and stabilizing oncogenic mRNAs.
    Oncogene. 2025 Jul 22. doi: 10.1038/s41388-025-03500.
    >> Share

    May 2025
  23. SONG C, Lin Y, Cai C, Tao K, et al
    LOXL2 reduces susceptibility to PARP inhibitors by promoting super-enhancer-regulated DNA damage repair in high-grade serous ovarian cancer.
    Oncogene. 2025 May 31. doi: 10.1038/s41388-025-03466.
    >> Share

  24. NARAYANA RVL, Gupta R
    Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03448.
    >> Share

    April 2025
  25. ZHU Y, Abedini A, Rodriguez GM, McCloskey CW, et al
    Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression.
    Oncogene. 2025 Apr 12. doi: 10.1038/s41388-025-03387.
    >> Share

  26. LI Y, Chen Z, Gao Y, Liu Y, et al
    SNRPB-mediated regulation of DDX39A splicing promotes ovarian cancer progression by regulating alpha6 integrin subunit expression.
    Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03386.
    >> Share

  27. WAGNER V, Morton M, Dorayappan KDP, Gonzalez A, et al
    Circulating extracellular vesicles protein expression for early prediction of platinum-resistance in high-grade serous ovarian cancer.
    Oncogene. 2025 Apr 10. doi: 10.1038/s41388-025-03382.
    >> Share

    March 2025
  28. ZHAO X, Lai H, Li G, Qin Y, et al
    Rictor orchestrates beta-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer.
    Oncogene. 2025 Mar 25. doi: 10.1038/s41388-025-03351.
    >> Share

  29. WANG J, Yang F, Chen Y, Xing Y, et al
    A positive feedback loop of OTUD1 and c-Jun driven by leptin expedites stemness maintenance in ovarian cancer.
    Oncogene. 2025 Mar 19. doi: 10.1038/s41388-025-03342.
    >> Share

  30. FANG D, Chen H, Zhu JY, Wang W, et al
    Editorial Expression of Concern: Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03333.
    >> Share

    February 2025
  31. XI Q, Kunita A, Ogawa M, Ka M, et al
    Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.
    Oncogene. 2025 Feb 24. doi: 10.1038/s41388-025-03312.
    >> Share

  32. STEWART J, Krastev DB, Brough R, Zatreanu D, et al
    PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
    Oncogene. 2025 Feb 12. doi: 10.1038/s41388-024-03265.
    >> Share

    December 2024
  33. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    >> Share

  34. CHIA ML, Bulat F, Gaunt A, Ros S, et al
    Metabolic imaging distinguishes ovarian cancer subtypes and detects their early and variable responses to treatment.
    Oncogene. 2024 Dec 6. doi: 10.1038/s41388-024-03231.
    >> Share

    October 2024
  35. LI Y, Yang H, Li A, Chen B, et al
    CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03188.
    >> Share

  36. SHI J, Zhou R, Wang S, Liu Y, et al
    NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma.
    Oncogene. 2024 Oct 14. doi: 10.1038/s41388-024-03187.
    >> Share

  37. LIU Y, Li J, Xu J, Long Y, et al
    m(6)A-driven NAT10 translation facilitates fatty acid metabolic rewiring to suppress ferroptosis and promote ovarian tumorigenesis through enhancing ACOT7 mRNA acetylation.
    Oncogene. 2024 Oct 10. doi: 10.1038/s41388-024-03185.
    >> Share

    September 2024
  38. SANG X, Han J, Wang Z, Cai W, et al
    SGK1 suppresses ferroptosis in ovarian cancer via NRF2-dependent and -independent pathways.
    Oncogene. 2024 Sep 21. doi: 10.1038/s41388-024-03173.
    >> Share

  39. CHEN J, Shan W, Jia Q, Chen Y, et al
    USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2.
    Oncogene. 2024 Sep 10. doi: 10.1038/s41388-024-03151.
    >> Share

    August 2024
  40. ONJI H, Tate S, Sakaue T, Fujiwara K, et al
    Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks.
    Oncogene. 2024;43:2475-2489.
    >> Share

    June 2024
  41. GHEZELAYAGH TS, Kohrn BF, Fredrickson J, Krimmel-Morrison JD, et al
    TP53 somatic evolution in cervical liquid-based cytology and blood from individuals with and without ovarian cancer and BRCA1 or BRCA2 germline mutations.
    Oncogene. 2024 Jun 25. doi: 10.1038/s41388-024-03089.
    >> Share

    May 2024
  42. ZHANG C, Xu Y, Zhu X, Zhang X, et al
    Phosphorylation of FOXK2 at Thr13 and Ser30 by PDK2 sustains glycolysis through a positive feedback manner in ovarian cancer.
    Oncogene. 2024 May 11. doi: 10.1038/s41388-024-03052.
    >> Share

    April 2024
  43. SHAN W, Peng W, Chen Y, Wang Y, et al
    GSK3beta and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer.
    Oncogene. 2024 Apr 25. doi: 10.1038/s41388-024-03040.
    >> Share

  44. CHEN H, Lee LJ, Vincent KM, Xu Z, et al
    Transcription factor ZIC2 regulates the tumorigenic phenotypes associated with both bulk and cancer stem cells in epithelial ovarian cancer.
    Oncogene. 2024 Apr 9. doi: 10.1038/s41388-024-03026.
    >> Share

  45. WEI Y, Chen Z, Li Y, Song K, et al
    The splicing factor WBP11 mediates MCM7 intron retention to promote the malignant progression of ovarian cancer.
    Oncogene. 2024 Apr 1. doi: 10.1038/s41388-024-03015.
    >> Share

    January 2024
  46. WU J, Wu Y, Chen S, Guo Q, et al
    PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/beta-catenin signalling pathway.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02943.
    >> Share

  47. LIU H, Deng S, Yao X, Liu Y, et al
    Ascites exosomal lncRNA PLADE enhances platinum sensitivity by inducing R-loops in ovarian cancer.
    Oncogene. 2024 Jan 15. doi: 10.1038/s41388-024-02940.
    >> Share

  48. WU CJ, Pan KF, Chen JQ, Tao Y-, et al
    Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment.
    Oncogene. 2024 Jan 4. doi: 10.1038/s41388-023-02918.
    >> Share

    December 2023
  49. YU X, Zhao P, Luo Q, Wu X, et al
    RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-kappaB activation and ovarian cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02910.
    >> Share

    November 2023
  50. AKINJIYAN FA, Ibitoye Z, Zhao P, Shriver LP, et al
    DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02884.
    >> Share

  51. CALLENS C, Rodrigues M, Briaux A, Frouin E, et al
    Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
    Oncogene. 2023;42:3556-3563.
    >> Share

    October 2023
  52. TAO YP, Zhu HY, Shi QY, Wang CX, et al
    S1PR1 regulates ovarian cancer cell senescence through the PDK1-LATS1/2-YAP pathway.
    Oncogene. 2023 Oct 12. doi: 10.1038/s41388-023-02853.
    >> Share

  53. EL BABA R, Haidar Ahmad S, Monnien F, Mansar R, et al
    Polyploidy, EZH2 upregulation, and transformation in cytomegalovirus-infected human ovarian epithelial cells.
    Oncogene. 2023;42:3047-3061.
    >> Share

    September 2023
  54. PETTITT SJ, Shao N, Zatreanu D, Frankum J, et al
    A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-?11q splice variant.
    Oncogene. 2023;42:2701-2709.
    >> Share

    August 2023
  55. RAY U, Thirusangu P, Jin L, Xiao Y, et al
    PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.
    Oncogene. 2023 Aug 7. doi: 10.1038/s41388-023-02785.
    >> Share

    July 2023
  56. HEINZL N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, et al
    Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
    Oncogene. 2023 Jul 4. doi: 10.1038/s41388-023-02758.
    >> Share

    June 2023
  57. LI Y, Chen Z, Peng J, Yuan C, et al
    The splicing factor SNRPB promotes ovarian cancer progression through regulating aberrant exon skipping of POLA1 and BRCA2.
    Oncogene. 2023 Jun 30. doi: 10.1038/s41388-023-02763.
    >> Share

    April 2023
  58. JIANG Y, Song L, Lin Y, Nowialis P, et al
    ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02679.
    >> Share

    March 2023
  59. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
    Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
    >> Share

  60. CHEN K, Yuan X, Wang S, Zheng F, et al
    MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
    Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016